載入中
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
前收盤價
€3.16
−€0.16 · -4.82%
盤中時間採用ET。市場資料可能有所延遲。
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
日內區間
目前€3.16
52週區間
目前€3.16
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
11
估值過高
情緒
44
多空交錯
風險
66
高風險
動能
31
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
日內區間
目前€3.16
52週區間
目前€3.16
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（EUR） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 448.3萬 EUR | 919.8萬 EUR | 1747.7萬 EUR | 1217.9萬 EUR | 419.4萬 EUR |
| 銷貨成本 | 279.61萬 EUR | 388.11萬 EUR | −2.3萬 EUR | 99.5萬 EUR | 101.7萬 EUR |
| 毛利 | 151萬 EUR | 919.8萬 EUR | 1750萬 EUR | 1705.7萬 EUR | 419.4萬 EUR |
| 研究與開發 | 8360.76萬 EUR | 9088萬 EUR | 1.1億 EUR | 6046.9萬 EUR | 4845.2萬 EUR |
| 銷售、一般及管理費用 | 5389.2萬 EUR | 1709.9萬 EUR | 1560.7萬 EUR | 1549.5萬 EUR | 1152萬 EUR |
| 營業費用 | 1.37億 EUR | 1.07億 EUR | 1.2億 EUR | 7416.7萬 EUR | 5630.9萬 EUR |
| 利息收入 | 282.88萬 EUR | 114.3萬 EUR | 94.5萬 EUR | 39萬 EUR | 5.7萬 EUR |
| 利息支出 | 3229.6萬 EUR | 1217.8萬 EUR | 517.8萬 EUR | 70.7萬 EUR | 13.8萬 EUR |
| 折舊和攤銷 | 322.3萬 EUR | 519.8萬 EUR | 259.9萬 EUR | 169.8萬 EUR | 92.34萬 EUR |
| 營業利益 | −1.31億 EUR | −9755.8萬 EUR | −1.03億 EUR | −5711萬 EUR | −5211.4萬 EUR |
| 淨利 | −3.4億 EUR | −1.84億 EUR | −1.1億 EUR | −5427.4萬 EUR | −4963.6萬 EUR |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
€14.00
上漲空間 343.04%報告持有此股票曝險的交易所交易基金。
Simplify Propel Opportunities ETFSURI99.06萬1.30%7606.44萬 USD2.82%US$17.06-0.14%
State Street SPDR S&P International Small Cap ETFGWX39.25萬0.04%9.08億 USD0.40%US$45.56+0.93%
Harbor Health Care ETF (MEDI)MEDI11.29萬0.28%4144.63萬 USD0.80%US$32.48+1.81%
ActivePassive International Equity ETFAPIE4.37萬—11.41億 USD0.45%US$38.56+0.65%
State Street SPDR Portfolio Europe ETFSPEU2.49萬0.00%6.83億 USD0.07%US$53.13+0.68%Simplify Propel Opportunities ETFSURIState Street SPDR S&P International Small Cap ETFGWXHarbor Health Care ETF (MEDI)MEDIActivePassive International Equity ETFAPIEState Street SPDR Portfolio Europe ETFSPEUAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
